We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Antidepressants in Pregnancy Increase Risk of Miscarriage

By HospiMedica International staff writers
Posted on 07 Jun 2010
A new study has found a 68% increase in the overall risk of miscarriage in pregnant women using antidepressants.

Researchers from the University of Montreal (Canada) and the CHU Ste-Justine (Montreal, Canada) examined data on 5,124 women in Quebec (Canada) from a large population-based cohort of pregnant women who had clinically verified miscarriages at up to 20 weeks of gestation, and a large sample of women from the same registry who did not have a miscarriage. More...
Of those who miscarried, 284 (5.5%) had taken antidepressants during pregnancy.

The researchers found that selective serotonin reuptake inhibitors (SSRIs), especially paroxetine and venlafaxine, were associated with increased risk of miscarriage, as were higher daily doses of either antidepressant; a combination of different antidepressants further doubled the risk of miscarriages. The researchers urged physicians who have patients of childbearing age taking antidepressants, or pregnant patients who require antidepressant therapy early in pregnancy, to discuss the risks and benefits with them. The study was published in the June 2010 issue of the Canadian Medical Association Journal (CMAJ).

"These results, which suggest an overall class effect of selective serotonin reuptake inhibitors, are highly robust given the large number of users studied,” said senior author Anick Bérard, Ph.D., and colleagues of the faculty of pharmacy at the University of Montreal.

SSRIs are typically used in the treatment of depression, anxiety disorders, and some personality disorders. They are also typically effective and used in treating premature ejaculation problems as well as some cases of insomnia. SSRIs increase the extracellular level of the neurotransmitter serotonin by inhibiting its reuptake into the presynaptic cell, increasing the level of serotonin available to bind to the postsynaptic receptor.

Related Links:

University of Montreal
CHU Ste-Justine




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.